ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "immunology"

  • Abstract Number: 1589 • ACR Convergence 2023

    Epigenetic Regulation of DNMT3A by TFEB and DOT1L Through AMPK Signalling Orchestrates the Lysosomal Response of Macrophages During Gout and Clonal Hematopoiesis

    Isidoro Cobo1, Jessica Murillo-Saich2, Mohnish Alishala1, Stephen Calderon1, Roxana Coras3, Nathanael Spann1, Anyan Cheng4, Thomas Prohaska1, Babak Razani5, Robert Terkeltaub1, Benjamin Ebert6, Ru Liu Bryan7, Monica Guma8 and Christopher glass1, 1University of California San Diego, San Diego, CA, 2Department of Medicine, University of California San Diego, La Jolla, CA, 3Cedars-Sinai Medical Center, Los Angeles, CA, 4University of California San Diego, San Francisco, CA, 5Universit of Pittsburgh, Pittsburgh, PA, 6Dana-Farber Cancer Institute, Boston, MA, 7UCSD and VASDHS, San Diego, CA, 8San Diego VA Healthcare Service, La Jolla, CA

    Background/Purpose: Gout is the most common form of inflammatory arthritis worldwide, which is characterised by the deposition of monosodium urate crystals (MSUc) in the joints…
  • Abstract Number: 2055 • ACR Convergence 2023

    A Randomized Controlled Trial of Two Hepatitis a Vaccine Doses Among Adolescents with Juvenile Idiopathic Arthritis and Crohn’s Disease on Immunosuppressive Therapy: A Pilot Study

    Racheal Githumbi1, Susan Kuhn1, Carla Osiowy2, Jennifer DeBruyn1, Marvin Fritzler1, Nicole Johnson1, Otto G Vanderkooi1 and Heinrike Schmeling1, 1University of Calgary, Calgary, AB, Canada, 2National Microbiology Laboratory, Public Health Agency of Canada, Winnepig, MB, Canada

    Background/Purpose: Juvenile idiopathic arthritis (JIA) and Crohn's disease (CD) are now controlled using immunosuppressive medications. However, disease control comes at the risk of increased infection.…
  • Abstract Number: 2508 • ACR Convergence 2023

    Chronic IL-6 Trans-Signaling Enhances Stem Cell-Like Characteristics of Rheumatoid Arthritis Synovial Fibroblasts

    Anil Singh and Salahuddin Ahmed, Washington State university, Spokane, WA

    Background/Purpose: Chronic exposure to IL-6 trans-signaling has been shown to significantly impact the characteristics of rheumatoid arthritis synovial fibroblasts (RASFs). Previous studies have demonstrated that…
  • Abstract Number: 0005 • ACR Convergence 2023

    Obexelimab Inhibits B Cell Activation and May Interfere with B Cell Chemotaxis in IgG4-Related Disease

    Thomas Guy1, Hang Liu2, Vinay Mahajan2, Cory Perugino3, Zachary Wallace4, Shauna quinn5, Allen Poma6, Debra Zach7, John Stone8 and Shiv Pillai9, 1Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, 2Ragon Institute, Cambridge, MA, 3Massachusetts General Hospital, Boston, MA, 4Massachusetts General Hospital, Newton, MA, 5Zenas Biopharma, New York, NY, 6Zenas Biosciences, New York, NY, 7Exagen, Vista, CA, 8Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA, 9Harvard Medical School, Boston, MA

    Background/Purpose: Obexelimab is a bifunctional, non-cytolytic, humanized monoclonal antibody that binds CD19 and ligates FcγRIIb with high affinity. Data from a phase 2 clinical trial…
  • Abstract Number: 0089 • ACR Convergence 2023

    Pre-Clinical Characterization of MTX-101, a Novel Bispecific CD8 Treg Modulator with the Potential to Restore CD8 Treg Functions in Patients with Rheumatological Autoimmune Diseases

    Daniel Patton, Meghan Maurer, Nadine Morgan, Minh Pham, Daniel Boster, Justin Huard, Cathy Tan, Rachael Fasnacht, Monica Childs, Gleda Hermansky, Alex Chen, Susan Julien, Jennifer Gardell, Cathy McMahan, Courtney Crane and Kristine Swiderek, Mozart Therapeutics, Seattle, WA

    Background/Purpose: In healthy individuals, CD8 Treg activation leads to selective elimination of aberrantly activated self-reactive CD4 T cells to maintain immune balance. The CD8 Treg…
  • Abstract Number: 0727 • ACR Convergence 2023

    A Novel Active Pemphigus Vulgaris Mouse Model Induced by Immunization with TLR Ligand Adjuvanted Recombinant Desmoglein 3 Protein Vaccine

    Changxing Gao, Zijun Wang and Qianjin Lu, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China; Key Laboratory of Basic and Translational Research on Immune-Mediated Skin Diseases, Chinese Academy of Medical Sciences, Nanjing, China. 3. Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, China

    Background/Purpose: Pemphigus vulgaris (PV) is an autoimmune bullous skin disease mediated by desmoglein-3 (Dsg3) specific auto-antibody present in skin and mucosae. The binding of pathogenic…
  • Abstract Number: 1599 • ACR Convergence 2023

    Single-Cell RNA Sequencing Reveals Cellular Drivers of UV-mediated Skin Injury in Cutaneous Lupus

    Mitra Maz1, Feiyang Ma2, Mehrnaz Gharaee-Kermani2, Amanda Victory2, Amy Hurst2, Johann E. Gudjonsson2 and J. Michelle Kahlenberg2, 1University of Michigan Medical School, Ann Arbor, MI, 2University of Michigan, Ann Arbor, MI

    Background/Purpose: Ultraviolet light (UV) is a known trigger of cutaneous lupus erythematosus (CLE) flares in systemic lupus erythematosus (SLE) patients, yet cell populations and mechanisms…
  • Abstract Number: 2105 • ACR Convergence 2023

    Cohort-wide Immuno-phenotype Deconvolute Immunological and Clinical Heterogeneity Across Autoimmune Rheumatic Diseases

    Hiroaki Tanaka1, Yukinori Okada2, Shingo Nakayamada1, Yusuke Miyazaki3, Kyuto Sonehara4, Shinichi Namba5, Suguru Honda6, Yuya Shirai7, Kenichi Yamamoto5, Katsunori Ikari8, Masayoshi Harigai9, KOSHIRO SONOMOTO10 and Yoshiya Tanaka1, 1University of Occupational and Environmental Health, Kitakyushu, Japan, 2University of Tokyo / Osaka University / RIKEN, Tokyo, Japan, 3The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kiakyusyu Fukuoka, Japan, 4University of Tokyo, Tokyo, Japan, 5Osaka University, Osaka, Japan, 6Tokyo Women's Medical University, Tokyo, Japan, 7Osaka University, Suita, Japan, 8Tokyo Women's Medical University School of Medicine, Tokyo, Japan, 9Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, 10University of Occupational and Environmental Health, Beppu, Japan

    Background/Purpose: Autoimmune rheumatic diseases (AIRDs) are systemic but heterogeneous diseases characterized by orchestration of disrupted self-tolerance of immune systems. We face a challenge in characterizing…
  • Abstract Number: 2564 • ACR Convergence 2023

    The Effectiveness of a Fourth Dose of COVID-19 mRNA Vaccine in Patients with Systemic Autoimmune Rheumatic Diseases Using Immunomodulators: An Emulated Target Trial

    Jennifer Hanberg1, Xiaoqing Fu1, Xiaosong Wang2, Naomi Patel1, Yumeko Kawano2, Abigail Schiff2, Emily Kowalski2, Claire Cook1, Kathleen Vanni2, Krishan Guzzo1, Grace Qian2, Katarina Bade3, Alene Saavedra2, Rathnam Venkat2, Shruthi Srivatsan1, Yuqing Zhang4, Jeffrey Sparks5 and Zachary Wallace6, 1Massachusetts General Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, 5Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 6Massachusetts General Hospital, Newton, MA

    Background/Purpose: Many patients with systemic autoimmune rheumatic diseases (SARDs) using immunomodulators have blunted humoral responses to COVID-19 vaccines. As such, the initial mRNA vaccine series…
  • Abstract Number: 0010 • ACR Convergence 2023

    A Potential Mechanism for Major Adverse Cardiac Events Associated with JAK Inhibitors: JAK Inhibitor Withdrawal Causes Urokinase Release by Primed STAT Signaling

    Sara McCoy1, Ilya Gurevic2 and jacques Galipeau2, 1University of Wisconsin School of Medicine and Public Health, Middleton, WI, 2University of Wisconsin, Madison, WI

    Background/Purpose: Sjögren’s Disease (SjD) has high glandular IFNg levels, associated with disease activity and lymphoma risk. We showed that IFNg-stimulated minor salivary gland (SG)-mesenchymal stromal…
  • Abstract Number: 0092 • ACR Convergence 2023

    Multi-omics Immune Profiling of Cytotoxic T Cells from Ankylosing Spondylitis Patients Identified a Subset of Clonally Exapnded CTLs That Evade Immune Exhaustion

    Michael Tang1, Zoya Qaiyum2, Melissa Lim1 and Robert Inman1, 1University Health Network, Toronto, ON, Canada, 2Krembil Research Institute, Toronto, ON, Canada

    Background/Purpose: Sustained chronic inflammation in the spine and of the sacroiliac joints is a key feature in Ankylosing Spondylitis (AS). A central role of CTL…
  • Abstract Number: 0838 • ACR Convergence 2023

    Infusion of Etanercept into the Peripheral Lymphatics Significantly Reduces Disease Activity in Rheumatoid Arthritis Patients with Inadequate Response to Subcutaneous Injections

    Russell Ross1, Vibeke Strand2, Roel Querubin3, John Goldman4, Richard Leff5, Alexis Melson1, Pei-Ling Roerig6 and Alan Smith7, 1Sorrento Therapeutics, Atlanta, GA, 2Stanford University, Portola Valley, CA, 3Marietta Rheumatology Associates, Marietta, GA, 4Northside Hospital, Atlanta, GA, 5Kezar Life Sciences, Chadds Ford, PA, 64P Therapeutics, Orlando, FL, 74P Therapeutics, Atlanta, GA

    Background/Purpose: The lymphatic system serves as a conduit for transporting immune cells and inflammatory molecules present in arthritic joints to lymph nodes (LN), playing a…
  • Abstract Number: 1637 • ACR Convergence 2023

    IgG-Fc-N-Sialylation and -Galactosylation in Primary Sjögren’s Syndrome (Pss) in Its Potential as Marker of Disease State and Disease Activity

    Helena Achten1, Liselotte Deroo2, Kristel De Boeck3, Matthias Jarlborg1, Tine Decruy1, Joke Deprez1, Emilie Dumas1, Dirk Elewaut4 and isabelle peene5, 1Ghent University, Ghent, Belgium, 2Ghent University, Gent, Belgium, 3Ghent University Hospital, Ghent, Belgium, 4Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, 5University Hospital Ghent, Ghent, Belgium

    Background/Purpose: Loss of galactose and sialic acid structures attached to the IgG-Fc-fragment switches the antibody effector function from anti-inflammatory to pro-inflammatory1. This study investigated the…
  • Abstract Number: 2184 • ACR Convergence 2023

    Development of Salivary Gland Organoids to Study Sjögren Syndrome

    Loïc Meudec1, Negaar Goudarzi2, Juliette Pascaud3, Fanny Jaulin2, Xavier Mariette4 and Gaetane Nocturne5, 1CHU Kremlin-Bicêtre, Rheumatology, Le Kremlin-Bicêtre, France, 2INSERM UMR 981, Institut Gustave Roussy, Villejuif, France, Villejuif, France, 3Center for Immunology of Viral Infections and Autoimmune Diseases, INSERM UMR 1184, FHU CARE, Université Paris-Saclay, Le Kremlin-Bicêtre, France, 4Université Paris-Saclay, Le Kremlin-Bicêtre, France, 5APHP, Le Kremlin-Bicêtre, France

    Background/Purpose: Sjögren disease (Sjo) is an autoimmune disease characterized by the infiltration of exocrine glands by immune cells, especially salivary glands (SG). SG epithelial cells…
  • Abstract Number: 0022 • ACR Convergence 2023

    Validation of a Transcriptomic-Based Machine Learning Model to Establish the Endotype of SLE Patients

    Erika Hubbard1, Prathyusha Bachali2, Kathryn Kingsmore Allison1, Amrie Grammer1 and Peter Lipsky1, 1AMPEL BioSolutions, Charlottesville, VA, 2AMPEL BioSolutions, Redmond, WA

    Background/Purpose: We previously developed a novel machine learning (ML) pipeline leveraging analysis of gene expression data to identify subsets of SLE patients with common molecular…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 26
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology